CEO Jan van de Winkel: New cancer drug is Genmab's most important milestone next year
Genmab expects to launch epcoritamab in the US and the EU in 2023.
by marketwire, translated by helene von tabouillot
Genmab is working hard to prepare the most important event of next year – the launch of cancer drug epcoritamab.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Genmab and Abbvie file for cancer drug approval in Japan
For subscribers
Ferring gets cancer nod from FDA
For subscribers
